InspireMD Launches Proposed Public Offering; Funding Amount Not Yet Determined
Key Facts
On November 12, 2026, InspireMD announced the launch of a proposed public offering of its ordinary shares to finance its operations, without disclosing a target size, price or final terms. The structure includes pre-funded warrants in lieu of shares for some investors, alongside accompanying ordinary warrants to purchase shares or pre-funded warrants. The company said all securities offered would be issued by it. It gave no assurance that the offering would be completed, or of its timing, size or terms, noting that these would depend on market conditions and other factors. It plans to use net proceeds, if any, for research and development, sales and marketing, working capital and other general purposes.
The company did not specify a target amount to raise or announce the number or price of shares or warrants to be offered. The proposed mix of securities means some investors may receive pre-funded warrants instead of ordinary shares, while ordinary warrants to purchase shares or pre-funded warrants would accompany the offering. Details of these instruments, including their final terms, have not yet been disclosed. The company said the offering’s size and actual terms had not been determined. The offering may result in the issuance of new securities, but the company did not estimate the impact on shareholders’ stakes.
InspireMD appointed Lake Street Capital Markets as sole book-running manager for the proposed offering. The book-running manager coordinates investor orders during marketing and pricing, but the announcement did not include an offering price or the number of securities. The company said the offering would be made under an effective shelf registration statement on Form S-3. It filed the registration statement on April 1, 2025, and the U.S. Securities and Exchange Commission declared it effective on April 10, 2025. That framework alone does not determine how much funding the company will raise in the current offering.
The company said a preliminary prospectus supplement and accompanying base prospectus would be filed with the U.S. Securities and Exchange Commission in connection with the offering. It added that final terms would be disclosed in a final prospectus supplement. The announcement did not specify when these documents would be published or when the transaction would be completed. It also left open whether the offering would be completed and its timing and size, subject to market conditions and other factors. The amount of funding, number of shares or warrants, and their pricing therefore remain subject to final disclosures.
The announcement followed NSPR shares closing at $0.80 in the November 11, 2026 session. The offering announcement did not give a new share price or report a market response after its release. In its third-quarter 2026 results, the company said revenue was $2,242,000, down 11.1% from $2,523,000 in the same period of 2025. The company attributed the lower year-over-year comparison in U.S. sales to the voluntary recall of its delivery system in May 2026. International sales were $2,210,000, up 9.1% from $2,026,000 a year earlier, while U.S. sales were $32,000, compared with $497,000.
Company data showed cash, cash equivalents and marketable securities totaled $19,246,000 on September 30, 2026, compared with $54,211,000 on December 31, 2025. InspireMD posted a net loss of $9,762,000 in the third quarter of 2026, compared with $12,708,000 in the same quarter of 2025. For the nine months ended September 30, 2026, the net loss was $37,775,000, compared with $37,025,000 in the same period of 2025. These results place the proposed use of proceeds, including research and development, marketing and working capital, within the operating needs the company identified in its offering announcement. It did not specify how much would be allocated to any of those items.
As part of its commercial plans, InspireMD expects to begin U.S. sales of the CGuard Prime system in the fourth quarter of 2026. The company said approval to use the system in TCAR procedures is supported by data from the pivotal CGUARDIANS II study. The study data, according to the company, showed a 100% acute device success rate. It also said there were no deaths, strokes, myocardial infarctions or stent thromboses within 30 days. The expected sales start falls in the same quarter as the proposed offering announcement, while execution of the offering and its final terms remain uncertain.